AE Risk Examined for Abiraterone, Enzalutamide in Prostate Cancer
Risk for metabolic or cardiovascular adverse events increased for men receiving abiraterone or enzalutamide for advanced disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.